These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 23540840

  • 1. Trying times for generic medicines in the USA.
    Lancet; 2013 Mar 30; 381(9872):1072. PubMed ID: 23540840
    [No Abstract] [Full Text] [Related]

  • 2. Lawsuits anticipated on generic biologicals front.
    Fox JL.
    Nat Biotechnol; 2003 Jul 30; 21(7):721-2. PubMed ID: 12833078
    [No Abstract] [Full Text] [Related]

  • 3. Warning label limbo. FDA rule letting generic-drug makers update risk alerts draws heavy flak.
    Carlson J.
    Mod Healthc; 2014 Jun 30; 44(26):20-2. PubMed ID: 25134408
    [No Abstract] [Full Text] [Related]

  • 4. PLIVA v. Mensing: generic consumers' unfortunate hand.
    Lee SB.
    Yale J Health Policy Law Ethics; 2012 Jun 30; 12(2):209-63. PubMed ID: 23175916
    [No Abstract] [Full Text] [Related]

  • 5. Consistency in the safety labeling of bioequivalent medications.
    Duke J, Friedlin J, Li X.
    Pharmacoepidemiol Drug Saf; 2013 Mar 30; 22(3):294-301. PubMed ID: 23042584
    [Abstract] [Full Text] [Related]

  • 6. Generic and alternative brand-name pharmaceutical equivalents: select with caution.
    Hendeles L, Hochhaus G, Kazerounian S.
    Am J Hosp Pharm; 1993 Feb 30; 50(2):323-9. PubMed ID: 8480793
    [No Abstract] [Full Text] [Related]

  • 7. Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines.
    Heller WM.
    Am J Hosp Pharm; 1993 Feb 30; 50(2):318-22. PubMed ID: 8480792
    [No Abstract] [Full Text] [Related]

  • 8. Impossible? Outlawing state safety laws for generic drugs.
    Glantz LH, Annas GJ.
    N Engl J Med; 2011 Aug 25; 365(8):681-3. PubMed ID: 21830958
    [No Abstract] [Full Text] [Related]

  • 9. US drug regulator warns manufacturers that it will not accept data from Indian research center.
    Dyer O.
    BMJ; 2016 Apr 29; 353():i2476. PubMed ID: 27130404
    [No Abstract] [Full Text] [Related]

  • 10. Labeling may differ between generic, brand-name products.
    Traynor K.
    Am J Health Syst Pharm; 2002 May 15; 59(10):912, 914. PubMed ID: 12040726
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Insights of biosimilars through SWOT analysis.
    Patel MM, Shah PJ, Patel BM.
    Expert Opin Biol Ther; 2014 Feb 15; 14(2):139-44. PubMed ID: 24151903
    [No Abstract] [Full Text] [Related]

  • 14. 'Biosimilar' drugs poised to penetrate market.
    Ledford H.
    Nature; 2010 Nov 04; 468(7320):18-9. PubMed ID: 21048737
    [No Abstract] [Full Text] [Related]

  • 15. Multinational medicines--ensuring drug quality in an era of global manufacturing.
    Okie S.
    N Engl J Med; 2009 Aug 20; 361(8):737-40. PubMed ID: 19692686
    [No Abstract] [Full Text] [Related]

  • 16. Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels.
    Boumil MM, Curfman G.
    JAMA; 2018 Aug 14; 320(6):547-548. PubMed ID: 30039167
    [No Abstract] [Full Text] [Related]

  • 17. FDA proposes more stringent pediatric-use labeling of prescription drug products.
    Clin Pharm; 1993 Jan 14; 12(1):6. PubMed ID: 8428434
    [No Abstract] [Full Text] [Related]

  • 18. Bioequivalence/bioavailability retention samples.
    Ransom C.
    Qual Assur; 1993 Jan 14; 2(1-2):42-3. PubMed ID: 8156218
    [No Abstract] [Full Text] [Related]

  • 19. FDA off-track on off-label drug promotion.
    Lancet; 2007 Dec 15; 370(9604):1976. PubMed ID: 18083382
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.